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Propranolol was introduced as a treatment for infantile hemangiomas (IH). We report a summary of 13 cases
of IH treated with propranolol and discuss its effectiveness. In our series, propranolol therapy was initiated at the
mean age of 4.1 months (1-8 months), and the mean therapy duration was 15 months (9-20 months). All patients
showed good clinical response. Only one patient experienced asymptomatic hypoglycemia as the side effect of the
drug. To avoid the side effect, the dose was increased slowly, with a feeding interval of 3 or 4 hours. Under these
conditions, hypoglycemia did not recur, which enabled treatment continuation. Propranolol conferred a risk of
bronchial constriction that lead to wheezy bronchitis. One patient had wheezy respiration when he contracted a
viral infection, during which time he stopped taking propranolol and resumed the treatment after 1 week. She
showed no deterioration of bronchial symptoms and could complete the therapy.
Adverse events such as hypoglycemia or low blood pressure might lead to a serious condition; thus, during
therapy initiation, hospitalization and careful monitoring are needed. During home care after the initial hospitali-
zation, frequent feeding and careful observation should be recommended with the medical staff’s advice. With
these considerations about adverse effects, propranolol therapy seems safe, effective, and easy, and should be the
first-line therapeutic option.

















：南雲薫子 〒162―8666 東京都新宿区河田町 8―1 東京女子医科大学病院小児科
E-mail: motoe.kaoruko@twmu.ac.jp
doi: 10.24488/jtwmu.88.4_99




東女医大誌 第 88巻 第 4号


























じて，0.5 mg/kg/日分 3で内服を開始し，1.0 mg/
















































とに 1.0 mg/kg/日，2.0 mg/kg/日と増量した．一旦













































1 Face Not noted Risk of 
covered eye





1×1 Risk of 
covered eye





4×4 Ulceration 2 23 19 2 - 8 Slightly 
erythematous 
(36)
4 Neck 5×4 Disfigure-
ment









1×2 Risk of 
covered eye
4 24 20 3 Wheezing 7 Disappearance 
of elevation 
(12)





2 Still in 
treatment









6 Still in 
treatment








3 12 9 3 - 9 Slightly 
erythematous 
(14)
10 Knee 5×6 Functional 
disorder
5 Still in 
treatment
- 3 - 8 Disappearance 
of elevation 
(7)
11 Shoulder 6×5×3 Bleeding 
tendency
8 Still in 
treatment





4×4 Risk of 
airway 
obstruction
4 Still in 
treatment
- 3 Hypoglycemia 16 Decreased 
volume 
(4)
13 Body 3×2 Ulceration 4 Still in 
treatment
- 3 - 9 No ulceration 
(5)
Case 1 ～ 7: Inderal Ⓡ , Case 8 ～ 13: Hemangiol Ⓡ　Syrup for Pediatric.





























 Left: Before the therapy (2 months old).
Right: Just after finishing the therapy (23 months old).
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